检索结果-南通市图书馆

COVID-19 therapeutics:Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery

引用

Genes & Diseases 2023年第4期10卷 1402-1428页

作者： Sunny Kumar Malini Basu pratyasha ghosh Uttam Pal Mrinal K.ghosh Cancer Biology and Inflammatory Disorder Division Council of Scientific and Industrial Research-Indian Institute of Chemical Biology(CSIR-IICB)TRUE CampusCN-6SectoreVSalt LakeKolkata-700091&4Raja S.C.Mullick RoadJadavpurKolkata 700032India Department of Microbiology Dhruba Chand Halder CollegeDakshin BarasatWest Bengal 743372India Department of Economics Bethune CollegeUniversity of CalcuttaKolkata 700006India

Severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)causes the compli-cated disease *** are continuously facing huge problems in the treatment of patients,as COVID-19-specific drugs are not available,hence the principle of drug repurpos-ing serves as a one-and-only ***,the repurposing of many drugs is underway;few of them are already approved by the regulatory bodies for their clinical use and most of them are in different phases of clinical *** in this review,our main aim is to discuss in detail the up-to-date information on the target-based pharmacological classification of repurposed drugs,the potential mechanism of actions,and the current clinical trial status of various drugs which are under repurposing since early *** last,we briefly proposed the probable phar-macological and therapeutic drug targets that may be preferred as a futuristic drug discovery approach in the development of effective medicines.

关键词： Clinical trials COVID-19 Drug discovery Pharmacology Repurposing of drugs SARS-CoV-2

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Targeting PD-1/PD-L1 in cancer immunotherapy:An effective strategy for treatment of triple-negative breast cancer(TNBC)patients

引用

Genes & Diseases 2023年第4期10卷 1318-1350页

作者： Sunny Kumar Mouli Chatterjee pratyasha ghosh Kirat K.Ganguly Malini Basu Mrinal K.ghosh Cancer Biology and Inflammatory Disorder Division Council of Scientific and Industrial Research-Indian Institute of Chemical Biology(CSIR-IICB)TRUE CampusCN-6SectoreVSalt LakeKolkata 700091JadavpurKolkataPIN 700032India Department of Economics Bethune CollegeUniversity of CalcuttaKolkataPIN 700006India Department of Microbiology Michael Madhusudan Memorial CollegeDurgapurPIN 713216India Department of Microbiology Dhruba Chand Halder CollegeUniversity of CalcuttaKolkataPIN 743372India

Maintaining the balance between eliciting immune responses against foreign pro-teins and tolerating self-proteins is crucial for maintenance of *** functions of programmed death protein 1(PD-1)and its ligand programmed death ligand 1(PD-L1)are to inhibit immune responses so that over-reacting immune cells does not cause any damage to its own body ***,cancer cells hijack this mechanism to attenuate immune cells functions and create an immunosuppressive environment that fuel their continuous growth and *** the past few years’rapid development in cancer immunotherapy has opened a new avenue in cancer *** of PD-1 and PD-L1 has become a potential strategy that rescue the functions of immune cells to fight against cancer with high ***,immune checkpoint monotherapies were not very successful,making breast cancer less ***,recent reports support the presence of tumor infiltrating lympho-cytes(TILs)in breast cancer that make it favorable for PD-1/PD-L1 mediated immunotherapy,which is effective in PD-L1 positive ***,anti-PD-1(pembrolizumab)and anti-PD-L1(atezolizumab)gets FDA approval for breast cancer treatment and make PD-1/PD-L1 immunotherapy is meaningful for further ***,this article gathered understand-ing of PD-1 and PD-L1 in recent years,their signaling networks,interaction with other mole-cules,regulations of their expressions and functions in both normal and tumor tissue microenvironments are crucial to find and design therapeutic agents that block this pathway and improve the treatment ***,authors collected and highlighted most of the important clinical trial reports on monotherapy and combination therapy.

关键词： Breast cancer Cancer Clinical trial Immunotherapy PD-1/PD-L1 TNBC

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：